<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00089466</url>
  </required_header>
  <id_info>
    <org_study_id>A5210</org_study_id>
    <secondary_id>10020</secondary_id>
    <secondary_id>ACTG A5210</secondary_id>
    <nct_id>NCT00089466</nct_id>
  </id_info>
  <brief_title>Safety and Activity of the Oral HIV Entry Inhibitor AMD11070 in HIV Infected Patients</brief_title>
  <official_title>Phase IB/IIA Dose-Finding Safety and Activity Study of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor) in HIV-Infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AIDS Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      New treatment options are critical for treatment-experienced HIV infected patients with drug&#xD;
      resistance. HIV entry inhibitors have been shown effective in patients with resistance to&#xD;
      other anti-HIV drugs. This study will test the safety and anti-HIV activity of eight&#xD;
      different doses of the HIV entry inhibitor AMD11070 (also known as AMD070) in HIV infected&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AMD11070 is an oral HIV-1 entry inhibitor that targets the CXCR4 receptor on T cells.&#xD;
      AMD11070 has been shown safe and well-tolerated in Phase I clinical trials in HIV uninfected&#xD;
      people. The goal of this study is to evaluate the safety and antiretroviral activity of eight&#xD;
      dose levels of AMD11070 in HIV infected adults with X4-tropic virus. Pharmacokinetics (PK) of&#xD;
      AMD11070 will also be studied.&#xD;
&#xD;
      This study will last 90 days. All participants will receive medication for 10 days. There are&#xD;
      eight cohorts in this study, with a maximum of six participants per cohort. Cohort A will&#xD;
      receive 200 mg AMD11070 every 12 hours; Cohort B will receive 400 mg AMD11070 every 12 hours;&#xD;
      Cohort C will receive 600 mg AMD11070 every 12 hours; Cohort D will receive 800 mg AMD11070&#xD;
      every 12 hours; Cohort E will receive 1000 mg AMD11070 daily; Cohort F will receive 1500 mg&#xD;
      AMD11070 daily; Cohort G will receive 1000 mg AMD11070 every 12 hours; and Cohort H will&#xD;
      receive 2000 mg AMD11070 daily. Cohorts B, C, D, and E will open sequentially, provided no&#xD;
      more than one of six participants in the preceding cohort experiences dose-limiting toxicity&#xD;
      (DLT) based on safety evaluations through Day 17. Cohort G will open to enrollment when&#xD;
      Cohort E is filled; Cohort H will open to enrollment when Cohort F is filled. Cohort F will&#xD;
      open to enrollment provided no more than one of six participants of Cohorts E and G&#xD;
      experiences DLT. All study participants will be offered to receive open-label AMD11070&#xD;
      through a separate long-term safety study.&#xD;
&#xD;
      Participants will either be admitted to the general clinical research center (GCRC) for the&#xD;
      dosing period or have dosing, PK testing, and other study monitoring done on an outpatient&#xD;
      basis, depending on the study site. Participants admitted to the GCRC for the dosing period&#xD;
      will be allowed daytime passes from the GCRC on Days 4, 6, 7, 8, and 9. During the study,&#xD;
      participants will have continuous heart monitoring, serial electrocardiograms (EKGs), and&#xD;
      vital sign checks. Fasting blood collection will occur on Days 5 and 10. Trough PK testing&#xD;
      will occur at entry and on Days 1, 2, 3, 4, 6, 8, and 11. Intensive 24-hour PK testing and&#xD;
      24-hour urine collection will occur on Days 10 and 11. After treatment, targeted physicals&#xD;
      and urine collection will occur on Days 17, 30, and 90, and additional blood collection will&#xD;
      occur on Days 17, 21, 30, and 90. Participants will undergo an EKG on Days 17 and 90.&#xD;
      Participants will also undergo an opthalmologic evaluation and questionnaire sometime after&#xD;
      receiving AMD11070.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicities of Grade 3 or greater</measure>
    <time_frame>during the 10 days of treatment or the 7 days after stopping treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction in X4-tropic virus from baseline of 1 log10 relative luciferase units (rlu)</measure>
    <time_frame>day 10</time_frame>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg AMD11070 every 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg AMD11070 every 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg AMD11070 every 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800 mg AMD11070 every 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000 mg AMD11070 daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1500 mg AMD11070 daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000 mg AMD11070 every 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2000 mg AMD11070 daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMD11070</intervention_name>
    <description>AMD11070 taken daily. Dosage dependent on arm.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
    <arm_group_label>E</arm_group_label>
    <arm_group_label>F</arm_group_label>
    <arm_group_label>G</arm_group_label>
    <arm_group_label>H</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV-1 infected&#xD;
&#xD;
          -  Have X4- or dual/mixed-tropic virus confirmed no more than 56 days prior to study&#xD;
             entry&#xD;
&#xD;
          -  HIV-1 viral load of 5,000 copies/ml or more within 60 days prior to study entry&#xD;
&#xD;
          -  If female, willing to discontinue hormonal contraception 1 week prior to study entry&#xD;
&#xD;
          -  Willing to use acceptable forms of contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Antiretroviral treatment within 14 days prior to study entry&#xD;
&#xD;
          -  Other prescription medications, herbal supplements, or aspirin within 7 days prior to&#xD;
             study entry. Patients taking medication for prophylaxis for Pneumocystis carinii&#xD;
             pneumonia (PCP) are not excluded. Patients taking medications approved by protocol&#xD;
             officials are not excluded, provided they have been on a stable dose for at least 14&#xD;
             days prior to study entry.&#xD;
&#xD;
          -  Nonsteroidal anti-inflammatory drugs (NSAIDS), over the counter medications, or other&#xD;
             supplements (including multivitamins) within 1 day prior to study entry&#xD;
&#xD;
          -  Heavy exercise within 24 hours before study entry evaluations are done&#xD;
&#xD;
          -  Immunizations within 30 days prior to study entry&#xD;
&#xD;
          -  Radiation therapy, cytotoxic chemotherapeutic agents, or immunomodulatory agents&#xD;
             within 30 days prior to study entry&#xD;
&#xD;
          -  Current use of some CYP substrates, inhibitors, or inducers. Use of CYP450 substrates&#xD;
             is allowed, except for CYP2D6 and CYP2C8 substrates.&#xD;
&#xD;
          -  Current use of P-gp inducers or inhibitors&#xD;
&#xD;
          -  Allergy or sensitivity to study drug or its formulations&#xD;
&#xD;
          -  Active infection or acute illness within 14 days prior to study entry, including&#xD;
             HIV-associated opportunistic infections&#xD;
&#xD;
          -  History of heart abnormalities. Patients with any repolarization delay (QTc interval&#xD;
             of greater than 500 msec) or a history of additional risk factors for torsade de&#xD;
             pointes (e.g., heart failure, hypokalemia) are also excluded.&#xD;
&#xD;
          -  Drug or alcohol abuse or dependence or other medical or psychological condition that,&#xD;
             in the opinion of the investigator, would interfere with the study or put participants&#xD;
             at undue risk&#xD;
&#xD;
          -  Chronic diarrhea, defined as having more than 3 stools/day for more than 4 weeks prior&#xD;
             to study entry&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael S. Saag, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Therapeutics CRS</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35924-2050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ponce de Leon Ctr. CRS</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Univ. School of Medicine, Infectious Disease Research Clinic</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://aidsinfo.nih.gov/ContentFiles/HIVLifeCycle_FS_en.pdf</url>
    <description>Click here for more information about the HIV life cycle</description>
  </link>
  <link>
    <url>http://aidsinfo.nih.gov/clinicaltrials/htmltrials_sp.asp?an=1524</url>
    <description>Haga clic aquí para ver información sobre este ensayo clínico en español.</description>
  </link>
  <reference>
    <citation>De Clercq E. Emerging anti-HIV drugs. Expert Opin Emerg Drugs. 2005 May;10(2):241-73. Review.</citation>
    <PMID>15934866</PMID>
  </reference>
  <reference>
    <citation>Moore JP, Kitchen SG, Pugach P, Zack JA. The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses. 2004 Jan;20(1):111-26. Review.</citation>
    <PMID>15000703</PMID>
  </reference>
  <reference>
    <citation>Reeves JD, Piefer AJ. Emerging drug targets for antiretroviral therapy. Drugs. 2005;65(13):1747-66. Review.</citation>
    <PMID>16114975</PMID>
  </reference>
  <reference>
    <citation>Ruibal-Ares BH, Belmonte L, Baré PC, Parodi CM, Massud I, de Bracco MM. HIV-1 infection and chemokine receptor modulation. Curr HIV Res. 2004 Jan;2(1):39-50. Review.</citation>
    <PMID>15053339</PMID>
  </reference>
  <reference>
    <citation>Shaheen F, Collman RG. Co-receptor antagonists as HIV-1 entry inhibitors. Curr Opin Infect Dis. 2004 Feb;17(1):7-16. Review.</citation>
    <PMID>15090884</PMID>
  </reference>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>August 5, 2004</study_first_submitted>
  <study_first_submitted_qc>August 5, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2004</study_first_posted>
  <disposition_first_submitted>November 16, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>November 16, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 18, 2009</disposition_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Entry Inhibitors</keyword>
  <keyword>CXCR4 Entry Inhibitors</keyword>
  <keyword>Treatment Experienced</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

